Literature DB >> 18426407

Involvement of FKHRL1 in melanoma cell survival and death.

C Hilmi1, L Larribere, M Deckert, S Rocchi, S Giuliano, K Bille, J P Ortonne, R Ballotti, C Bertolotto.   

Abstract

Melanoma is a highly aggressive tumour characterized by a strong resistance to apoptotic stimuli that give rise to a selective advantage for tumour progression and metastasis formation. Therefore, it is of paramount importance to better understand the mechanisms involved in this resistance to apoptosis. In this report, we focused our attention on FKHRL1, a member of the forkhead family of transcription factors, which controls expression of genes involved in cell cycle progression and apoptosis. In melanoma cells, we show that IGF1, which exerts pro-survival properties, induces the phosphorylation and nuclear exclusion of FKHRL1 in a PI3K/AKT-dependent pathway. Moreover, we observe that over-expression of a non-phosphorylable mutant of FKHRL1 (FKHRL1-TM), constitutively localized to the nucleus, promotes apoptotic cell death of melanoma cells. Finally, we find that FKHRL1-TM decreases the expression of survivin, a member of the inhibitor of apoptosis protein and that survivin re-expression partially rescues the deleterious effects of FKHRL1. Taken together, these findings reveal, in melanoma cells, that endogenous FKHRL1 is a downstream target of the PI3K/AKT pathway and suggest that the phosphorylation of this transcription factor may be involved in the pro-survival effects of growth factors such as IGF1. On the other hand, forced nuclear localization of FKHRL1 decreases melanoma cell growth and may serve as a therapeutic strategy against melanoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18426407     DOI: 10.1111/j.1755-148X.2008.00440.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  8 in total

1.  Adenovirus-mediated expression of mutated forkhead human transcription like-1 suppresses tumor growth in a mouse melanoma xenograft model.

Authors:  Jorge G Gomez-Gutierrez; Michael E Egger; Hongying Hao; Heshan Sam Zhou; Kelly M McMasters
Journal:  Cancer Biol Ther       Date:  2012-08-15       Impact factor: 4.742

Review 2.  Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?

Authors:  Ahmed Lasfar; Karine A Cohen-Solal
Journal:  Carcinogenesis       Date:  2010-07-23       Impact factor: 4.944

3.  Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor.

Authors:  Miguel F Segura; Douglas Hanniford; Silvia Menendez; Linsey Reavie; Xuanyi Zou; Silvia Alvarez-Diaz; Jan Zakrzewski; Elen Blochin; Amy Rose; Dusan Bogunovic; David Polsky; Jianjun Wei; Peng Lee; Ilana Belitskaya-Levy; Nina Bhardwaj; Iman Osman; Eva Hernando
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

4.  Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways.

Authors:  Jairam Vanamala; Lavanya Reddivari; Sridhar Radhakrishnan; Chris Tarver
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

Review 5.  Nucleo-cytoplasmic transport as a therapeutic target of cancer.

Authors:  Giovanni Luca Gravina; William Senapedis; Dilara McCauley; Erkan Baloglu; Sharon Shacham; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-12-05       Impact factor: 17.388

Review 6.  p53: key conductor of all anti-acne therapies.

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2017-09-19       Impact factor: 5.531

7.  The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.

Authors:  Gabriela Nestal de Moraes; Paloma Silva Souza; Fernanda Casal de Faria Costas; Flavia Cunha Vasconcelos; Flaviana Ruade Souza Reis; Raquel Ciuvalschi Maia
Journal:  Leuk Res Treatment       Date:  2012-04-24

Review 8.  Targeting nucleocytoplasmic transport in cancer therapy.

Authors:  Richard Hill; Bastien Cautain; Nuria de Pedro; Wolfgang Link
Journal:  Oncotarget       Date:  2014-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.